CA2447909C - Use of proteasome inhibitors to treat dry eye disorders - Google Patents

Use of proteasome inhibitors to treat dry eye disorders Download PDF

Info

Publication number
CA2447909C
CA2447909C CA2447909A CA2447909A CA2447909C CA 2447909 C CA2447909 C CA 2447909C CA 2447909 A CA2447909 A CA 2447909A CA 2447909 A CA2447909 A CA 2447909A CA 2447909 C CA2447909 C CA 2447909C
Authority
CA
Canada
Prior art keywords
alkyl
dry eye
formula
proteasome inhibitors
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2447909A
Other languages
English (en)
French (fr)
Other versions
CA2447909A1 (en
Inventor
Peter G. Klimko
Mark R. Hellberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of CA2447909A1 publication Critical patent/CA2447909A1/en
Application granted granted Critical
Publication of CA2447909C publication Critical patent/CA2447909C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2447909A 2001-05-21 2002-05-17 Use of proteasome inhibitors to treat dry eye disorders Expired - Fee Related CA2447909C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29272201P 2001-05-21 2001-05-21
US60/292,722 2001-05-21
PCT/US2002/015775 WO2002094311A1 (en) 2001-05-21 2002-05-17 Use of proteasome inhibitors to treat dry eye disorders

Publications (2)

Publication Number Publication Date
CA2447909A1 CA2447909A1 (en) 2002-11-28
CA2447909C true CA2447909C (en) 2011-04-05

Family

ID=23125916

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2447909A Expired - Fee Related CA2447909C (en) 2001-05-21 2002-05-17 Use of proteasome inhibitors to treat dry eye disorders

Country Status (17)

Country Link
US (1) US6740674B2 (OSRAM)
EP (1) EP1392355B1 (OSRAM)
JP (1) JP2004530699A (OSRAM)
CN (1) CN1509183A (OSRAM)
AT (1) ATE353667T1 (OSRAM)
AU (1) AU2002308760B2 (OSRAM)
BR (1) BR0209883A (OSRAM)
CA (1) CA2447909C (OSRAM)
CY (1) CY1107531T1 (OSRAM)
DE (1) DE60218153T2 (OSRAM)
DK (1) DK1392355T3 (OSRAM)
ES (1) ES2278049T3 (OSRAM)
MX (1) MXPA03010634A (OSRAM)
PL (1) PL367287A1 (OSRAM)
PT (1) PT1392355E (OSRAM)
WO (1) WO2002094311A1 (OSRAM)
ZA (1) ZA200308768B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005099687A2 (en) 2004-04-09 2005-10-27 President And Fellows Of Harvard College Analogs of salinosporamide a
US20060167106A1 (en) * 2004-11-19 2006-07-27 Mei Zhang Compounds acting at the centrosome
US7465720B2 (en) 2005-09-12 2008-12-16 President And Fellows Of Harvard College Proteasome inhibiting β-lactam compounds
KR101434522B1 (ko) 2005-11-09 2014-08-26 오닉스 세라퓨틱스, 인크. 효소 저해를 위한 화합물
UA101303C2 (uk) 2006-06-19 2013-03-25 Протеолікс, Інк. Сполуки для інгібування ферменту протеасоми
ES2684340T3 (es) * 2007-10-04 2018-10-02 Onyx Therapeutics, Inc. Inhibidores de proteasa epoxi cetona de péptidos cristalinos y síntesis de cetoepóxidos de aminoácidos
AU2009308516B2 (en) 2008-10-21 2016-08-25 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
CA2791651C (en) 2010-03-01 2019-08-20 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
CA2795559A1 (en) 2010-04-07 2011-11-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
CN103893742B (zh) * 2014-03-03 2016-01-20 中山大学中山眼科中心 含卵黄膜外层蛋白1在制备治疗干眼药物中的应用
CN107151255A (zh) * 2016-03-06 2017-09-12 复旦大学 硼酸类化合物及其制备方法和用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991759A (en) 1975-10-28 1976-11-16 Alza Corporation Method and therapeutic system for treating aqueous deficient dry eye
US4131651A (en) 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4370325A (en) 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4744980A (en) 1986-04-28 1988-05-17 Holly Frank J Ophthalmic solution for treatment of dry eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US4818537A (en) 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US4966773A (en) 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
US5174988A (en) 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5583150A (en) 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
DE69115990T2 (de) 1990-05-29 1996-05-30 Ocular Res Of Bonton Inc Zusammensetzung zur Behandlung von Dry Eye Erkrankungen
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
ZA927277B (en) 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
US5958912A (en) 1992-04-21 1999-09-28 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
DE69326836T2 (de) 1992-04-21 2000-02-24 The Schepens Eye Research Institute, Inc. Androgentherapie am auge beim sjögrensyndrom
US6107289A (en) 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
US5290572A (en) 1992-08-06 1994-03-01 Deo Corporation Opthalmic composition for treating dry eye
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
WO1997020578A1 (en) 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
JPH1036289A (ja) 1996-07-24 1998-02-10 Sumitomo Pharmaceut Co Ltd 神経細胞の変性または死滅抑制剤
US6071904A (en) 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
WO1998035691A1 (en) 1997-02-15 1998-08-20 Proscript, Inc. Treatment of infarcts through inhibition of nf-kappab
WO1999015183A1 (en) 1997-09-25 1999-04-01 Proscript Inc. PROTEASOME INHIBITORS, UBIQUITIN PATHWAY INHIBITORS OR AGENTS THAT INTERFERE WITH THE ACTIVATION OF NF-λB VIA THE UBIQUITIN PROTEASOME PATHWAY TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES
CA2219867A1 (en) 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
DK1037627T3 (da) 1998-07-14 2001-10-01 Alcon Lab Inc Anvendelse af 11-(3-dimethylamino-propyliden)-6, 11-dihydrodibenz[b,e]oxepin-2-eddikesyre og af farmaceutisk acceptable salte deraf til fremstillingen af et lægemiddel til behandlingen af non-allergiske...
US6096733A (en) 1998-12-10 2000-08-01 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
AU3074500A (en) 1999-01-20 2000-08-07 Kyowa Hakko Kogyo Co. Ltd. Proteasome inhibitors
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
CA2370830C (en) 1999-04-27 2009-10-13 Novartis Ag Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors

Also Published As

Publication number Publication date
PT1392355E (pt) 2007-03-30
PL367287A1 (en) 2005-02-21
ATE353667T1 (de) 2007-03-15
US20030008910A1 (en) 2003-01-09
DE60218153D1 (de) 2007-03-29
US6740674B2 (en) 2004-05-25
CA2447909A1 (en) 2002-11-28
ZA200308768B (en) 2005-01-26
CY1107531T1 (el) 2013-03-13
DK1392355T3 (da) 2007-04-30
EP1392355A1 (en) 2004-03-03
DE60218153T2 (de) 2007-06-28
MXPA03010634A (es) 2004-03-09
AU2002308760B2 (en) 2006-05-11
BR0209883A (pt) 2004-06-08
CN1509183A (zh) 2004-06-30
JP2004530699A (ja) 2004-10-07
ES2278049T3 (es) 2007-08-01
EP1392355B1 (en) 2007-02-14
WO2002094311A1 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
CA2447909C (en) Use of proteasome inhibitors to treat dry eye disorders
US6645978B1 (en) Lipoxin A4 and its analogs for the treatment of dry eye
ZA200502119B (en) Use of cytokine synthesis inhibitors for the tratment of dry eye disorders
AU2002308760A1 (en) Use of proteasome inhibitors to treat dry eye disorders
US20030109509A1 (en) Methods for treating dry eye
JP2003513910A (ja) １５−ヒドロキシエイコサテトラエン酸のヘテロ原子分断類似体および使用方法
US6645994B1 (en) Method of treating dry eye disorders
US7112588B2 (en) Use of proteasome inhibitors to treat dry eye disorders
JP2003513947A (ja) １５−ヒドロキシエイコサテトラエン化合物およびその使用方法
US6458854B2 (en) Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use
EP1393277B1 (en) USE OF NF-Kappa-B INHIBITORS TO TREAT DRY EYE DISORDERS
US20030109488A1 (en) Methods for treating dry eye
AU2002309963A1 (en) Use of NF-KAPPA-B inhibitors to treat dry eye disorders
AU2002334697A1 (en) Methods for treating dry eye by a combination of an antiinflammatory steroid and a MUC-1 secretagogue

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170517